Coherus Presents Phase 2 Clinical Data On Casdozokitug, A First-in-Class IL-27-Targeted Antibody, At The 2024 ASCO GI Cancers Symposium; The Primary Endpoint Of The Lead-in Portion Of The Study Was Safety And Tolerability
Benzinga Newsdesk - Jan 18, 2024, 4:16PM